MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.msard.2023.104949

Медицинская библиотека · Multiple sclerosis and related disorders · 2023

Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.

Sen Sedat, Tuncer Asli, Terzi Murat, Bunul Sena Destan, Ozen-Acar Pinar, Altunrende Burcu, Ozakbas Serkan, Tutuncu Melih, Uygunoglu Ugur, Akman-Demir Gulsen, Karabudak Rana, Efendi Husnu, Siva Aksel

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune, inflammatory disease of the central nervous system affecting the optic nerves and spinal cord. Most NMOSD patients have autoantibodies against the astrocyte water channel protein aquaporin-4 (AQP4). Eculizumab treatment is used effectively and safely in AQP4-IgG+ NMOSD. Our study evaluated the prognosis and outcomes of all clinical trial (PREVENT) patients from Turkey who received eculizumab treatment for AQP4-IgG+ NMOSD.

METHOD: Clinical and demographic data of all patients enrolled in the PREVENT and OLE clinical trial in Turkey were analyzed during the study period and after the study ended. Clinical follow-up results were recorded in detail in patients who had to discontinue eculizumab treatment.

RESULTS

The study included 10 patients who participated in PREVENT and OLE. Seven patients completed the studies, three patients did not continue the study and were switched to other treatments. Only one of the seven patients was able to continue treatment after eculizumab was approved in AQP4-IgG+NMOSD. The other six patients could not continue treatment due to reimbursement conditions. Four of the six patients who could not continue eculizumab treatment experienced early relapse (within the first three months after stopping the drug). All of these patients had high disease activity before eculizumab and had never relapsed under eculizumab treatment over the long term.

CONCLUSION

Eculizumab was used effectively and safely in Turkish AQP4-IgG+NMOSD patients with high disease activity. Disease reactivation and relapse may occur after discontinuation of eculizumab treatment in patients with a long-term stable course. In these cases, close monitoring for disease reactivation is recommended.

Для цитирования: Sen Sedat, Tuncer Asli, Terzi Murat, Bunul Sena Destan, Ozen-Acar Pinar, Altunrende Burcu, Ozakbas Serkan, Tutuncu Melih, Uygunoglu Ugur, Akman-Demir Gulsen, Karabudak Rana, Efendi Husnu, Siva Aksel. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.. Multiple sclerosis and related disorders. 2023. DOI: 10.1016/j.msard.2023.104949.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.